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1. Introduction 
The term antiphospholipid antibodies syndrome (APS) defines an autoantibody induced 
thrombophilia, associated to recurrent thrombosis and pregnancy complications (Hughes, 
1993). Diagnosis of APS requires both serological positivity for antiphospholipid antibodies 
(aPL), a heterogeneous family of autoantibodies directed against protein phospholipid 
complexes, and the onset of the diagnostic clinical manifestations (see more below). Indeed, 
it has been widely shown that aPL are not sufficient per se to determine clinical 
manifestations of APS and that the likelihood that aPL may contribute to the pathogenesis of 
thrombosis or pregnancy complications, or both, varies between clinical settings (Meroni et 
al., 2004).  
To better define this complex syndrome, it must clarify that APS is commonly distinguished 
between “primary APS”, not associated to other autoimmune diseases, and “secondary 
APS”, when aPL serological positivity and clinical features of APS occur in the context of a 
known autoimmune disease. The majority of patients with secondary APS are affected from 
Systemic Lupus Erythematosus (SLE) and develop aPL serological positivity. About 40% of 
patients with SLE have aPL positivity (Mok et al., 2005) but less than 40% of them will 
eventually have thrombotic events (Ruiz-Irastorza et al., 2004; Tektonidou et al., 2009). 
Actually, it is still unknown if APS and SLE are two manifestations of the same disease or if 
underlying SLE could favour the development of APS (Miyakis et al., 2006). Accordingly, 
distinction between primary or secondary APS it is not so easy and have to be made 
carefully (Miyakis et al., 2006).  
2. Clinical manifestations of APS 
2.1 Systemic features 
Venous thrombosis, or embolism, are the most frequent manifestations of APS and might 
occur in any vascular vessel while, in congenital thrombophilias, mostly involve venous bed 
(Cervera, 2002). Among the arterial vessels, the central nervous system is the district most 
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often affected, usually in the form of stroke or transient ischaemic attack (Cervera et al., 
2002). aPL have also been associated with venous sinus thrombosis, myelopathy, chorea, 
migraine, and epilepsy (Sanna et al., 2003). Furthermore, in patients with SLE an association 
between serum anticardiolipin antibodies and cognitive impairment has been found (Hanly 
et al., 1999; Menon et al., 1999) as well as a mild cognitive dysfunction in more than 40% of 
patients with APS (Tektonidou et al., 2006).  
Cardiovascular features of APS include valvular disease, coronary artery disease, 
intracardiac thrombus formation, pulmonary hypertension and dilated cardiomyopathy 
(Koniari et al., 2010). Cardiac valvular pathology commonly affects the mitral valve, 
followed by the aortic and tricuspid ones, determining irregular thickening of the valve 
leaflets due to deposition of immune complexes that may lead to vegetations and valve 
dysfunction. These lesions are almost frequent and may be a significant risk factor for stroke 
(Khamashta et al., 1990; Koniari et al., 2010). 
Renal manifestations of APS generally took place as hypertension with proteinuria and renal 
insufficiency (Amigo et al., 1992; Tektonidou et al., 2004) with the most frequent renal 
histopathological features associated being thrombotic microangiopathy or, less often, fibrous 
intimal hyperplasia, focal cortical atrophy and arterial occlusions (Tektonidou et al., 2004).  
Other clinical features associated to APS are haematological alterations, like 
thrombocytopenia and haemolytic anaemia, skin ulcers, avascular bone necrosis and also 
the endocrinologic manifestation of adrenal insufficiency (Cervera et al., 2002). Livedo 
reticularis, found in about a quarter of patients with APS, represents a physical sign that 
often suggests to the clinician the right diagnosis and, among patients with APS, it also 
identifies those at a higher risk for arterial thrombosis (Ruiz-Irastorza et al., 2010; Francès et 
al., 2005). 
2.2 Adverse pregnancy outcomes associated to APS  
Beyond thromboses, obstetric complications are the other main features of APS. Such 
association is confirmed by several epidemiological studies and experimental models 
showing that passive transfer of aPL IgG induces foetal loss and growth retardation in 
pregnant naive mice, giving the proof that aPL are involved in determining the clinical 
manifestations of the syndrome (Meroni et al., 2010). 
The most common adverse pregnancy outcome associated to APS is recurrent miscarriage, 
defined as three or more unexplained consecutive miscarriages before the 10th week of 
gestation. Other obstetric features of APS are unexplained foetal deaths, occurring at or 
beyond the 10th week of gestation, and premature births of a morphologically healthy 
newborn baby before the 34th week of gestation because of eclampsia or severe pre-
eclampsia (Miyakis et al., 2006).  
Recurrent miscarriage occurs in about 1% of the general population attempting to have 
children (Stirrat, 1990) and about 10–15% of women with recurrent miscarriage are 
diagnosed with APS (Rai et al., 1995; Yetman & Kutteh, 1996). Foetal death in the second or 
third trimesters of pregnancy occurs in up to 5% of unselected pregnancies (Silver , 2007) 
but it is less likely as pregnancy advances (Smith et al., 2004). Although foetal death occurs 
significantly most often in APS (Oshiro et al., 1996), the overall contribution to the 
pathogenesis of this syndrome is unknown, because of the effect of other possible 
contributing factors such as underlying hypertension or pre-existing comorbidities, like SLE 
or renal diseases.  
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Pregnant women with diagnosis of APS are at increased risk for developing preeclampsia or 
placental insufficiency, but it is still unknown the precise relationship between aPL and the 
occurrence of such clinical manifestations (Clark et al., 2007). Furthermore, aPL seem to be 
detectable in 11–29% of women with preeclampsia, compared with 7% or less in controls 
and  in 25% of women delivering growth restricted foetuses (Clark et al., 2007). Finally, 
results from prospective cohort studies indicate that of pregnant women with high 
concentrations of aPL, 10–50% develop preeclampsia, and more than 10% of these women 
deliver infants who are small for gestational age (Clark et al., 2007). 
3. Diagnostic criteria 
According to the last International consensus statement for APS diagnostic criteria, in order 
to make diagnosis of the syndrome the combination of at least one clinical and one 
laboratory criterion is required (Miyakis et al., 2006) (Table 1). 
 
Clinical criteria Laboratory criteria 
Vascular thrombosis 
 One or more clinical episodes of arterial, venous, or 
small vessel thrombosis, in any tissue or organ. 
 
 Thrombosis should be supported by objective 
validated criteria—ie, unequivocal findings of 
appropriate imaging studies or histopathology. 
For histopathological support, thrombosis should 
be present without substantial evidence of 
inflammation in the vessel wall. 
 
Pregnancy morbidity, defined by one of the 
following criteria: 
 One or more unexplained deaths of a 
morphologically healthy foetus at or beyond the 
10th week of gestation, with healthy foetal 
morphology documented by ultrasound or by 
direct examination of the fetus. 
 One or more premature births of a morphologically 
healthy newborn baby before the 34th week of 
gestation because of: eclampsia or severe 
preeclampsia defined according to standard 
definitions or recognized features of placental 
failure. 
 Three or more unexplained consecutive 
spontaneous abortions before the 10th week of 
gestation, with maternal anatomical or hormonal 
abnormalities and paternal and maternal 
chromosomal causes excluded. In studies of 
populations of patients who have more than one 
type of pregnancy morbidity, investigators are 
strongly encouraged to stratify groups of patients 
according to one of the three criteria.
 Lupus anticoagulant present in plasma, 
on two or more occasions at least 12 
weeks apart, detected according to 
the guidelines of the International 
Society on Thrombosis and 
Hemostasis (Scientific Subcommittee 
on lupus anticoagulant/ 
phospholipid- dependent antibodies). 
 Anticardiolipin antibody of IgG or IgM 
isotype, or both, in serum or plasma, 
present in medium or high titres (ie, 
>40 GPL or MPL, or greater than the 
99th percentile) on two or more 
occasions, at least 12 weeks apart, 
measured by a standardized ELISA. 
 Anti-┚2-gycoprotein 1 antibody of IgG 
or IgM isotype, or both, in serum or 
plasma (in titres greater than the 99th 
percentile), present on two or more 
occasions, at least 12 weeks apart, 
measured by a standardized ELISA, 
according to recommended 
procedures. 
Table 1. Revised diagnostic criteria of APS (Miyakis et al., 2006). 
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4. Pathogenetic mechanisms mediated by aPL 
4.1 Vascular thrombosis 
The molecular mechanisms underlying thrombosis and foetal death in APS have long been 
investigated. The main target antigens reported in patients with APS include beta-2-
glycoprotein-1 (┚2GPI), prothrombin and annexin V (Galli et al., 2003). Other putative 
antigens are thrombin, protein C, protein S, thrombomodulin, tissue plasminogen activator, 
kininogens (high or low molecular), prekallikrein, factor VII/VIIa, factor XI, factor XII, 
complement component C4, heparan sulfate proteoglycan, heparin, oxidised low-density 
lipoproteins (Galli et al., 2003; Rand et al., 2010). The main autoantigens are attracted to 
negatively charged phospholipids exposed on the outer side of cell membranes in great 
amounts only under special circumstances such as damage or apoptosis (e.g. endothelial 
cell) or after activation (e.g. platelets) (Galli et al., 2003). 
Endothelial cells, activated by aPL with anti-┚2GPI activity, express adhesion molecules 
such as intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, 
and both endothelial cells and monocytes upregulate the production of tissue factor (TF) 
(Pierangeli et al., 2008). All at once, activated platelets increase expression of glycoprotein 
IIb-IIIa and synthesis of thromboxane A2, determining a procoagulant state (Figure 1). 
(Pierangeli et al., 2006; Pierangeli et al., 2008; Lopez-Pedrera et al., 2008; Montiel-Manzano et 
al., 2007; Vega-Ostertag et al., 2005). Additional mechanisms promoting clot formation could 
be represented by interaction of aPL with proteins implicated in clotting regulation; such as 
annexin A5, prothrombin, factor X, protein C and plasmin (de Groot & Derksen, 2005; 
Pierangeli et al., 2008; Rand et al., 2010).  
 
 
Fig. 1. aPL-mediated mechanism of trombosis.  
aPL are able to activate endothelial cells and platelets leading to a procoagulant state (first 
hit). The occurrence of a second hit, like inflammation, can lead to clot formation.  
Recent results from studies in mice highlight the role of inflammation in the pathogenesis of 
APS, showing a central role for complement activation in thrombosis and foetal loss induced 
by aPL (Pierangeli et al., 2005; Girardi et al., 2004). Because many individuals with high aPL 
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antibody titers remain asymptomatic, a second hit hypothesis have been proposed. It is 
likely that in the aPL-induced vascular procoagulant state, activation of the complement 
cascade might close the loop and provoke thrombosis, often in the presence of a second hit, 
like tobacco, inflammation, or oestrogens (Meroni et al., 2004; de Groot & Derksen, 2005; 
Ruiz-Irastorza et al., 2010).  
4.2 Placental thrombosis  
Based on the knowledge of the process of intravascular aPL-mediate clot formation (Figure 1), 
initially intraplacental thrombosis was considered the main pathogenic mechanism mediating 
foetal loss in APS. This hypothesis of placental damage was supported by the finding of 
thrombosis and infarction in placentas from women with APS and by the demonstration of 
aPL capability to induce a procoagulant state in vitro through several mechanisms including 
the ability of the aPL antibodies (specifically, anti-┚2GPI antibodies) to disrupt the 
anticoagulant annexin A5 shield on trophoblast and endothelial cell monolayers (Peaceman & 
Rehnberg, 1993; Nayar & Lage, 1996; Rand et al., 2010). Supporting the in vitro findings, a 
significantly lower distribution of annexin A5 covering the intervillous surfaces was found in 
the placentas of aPL-positive women in comparison with normal controls (Rand et al., 1994). 
Nevertheless,  thrombotic events cannot account for all of the histopathologic findings in 
placentae from women with APS and other mechanisms of reproductive impairment are likely 
to be involved (Out et al., 1991; Park, 2006). 
4.3 Defective placentation 
4.3.1 Trophoblast invasiveness impairment 
New aPL-mediated pathogenic mechanisms have been proposed during the last ten years: 
anti-┚2GPI antibodies seem to bind directly the maternal decidua and the invading 
trophoblast, determining defective placentation.  
On the foetal side, ┚2GPI has been shown to be expressed on trophoblast cell membranes, 
explaining the placental tropism of anti-┚2GPI antibodies. Being a cationic plasma protein, 
┚2GPI has been suggested to bind to exposed phosphatidylserine on the external cell 
membranes of trophoblasts undergoing syncitium formation (Meroni et al., 2010).  
┚2GPI-dependent antibodies can adhere to human trophoblast cells in vitro (Di Simone et al., 
2000), consistently with the hypothesis that the visibility of anionic PLs on the external cell 
surface during intertrophoblastic fusion might offer a useful substrate for the cation PL-
binding site (Katsuragawa et al., 1997; Rote et al., 1998). The binding to anionic structures 
induces the expression of new cryptic epitopes and/or increases the antigenic density, two 
events that are apparently pivotal for the antibody binding (Wang S.X. et al., 2000). In vitro 
studies with both murine and human monoclonal antibodies as well as with polyclonal IgG 
antibodies from APS patients have clearly demonstrated a binding to trophoblast monolayers 
(Lyden et al., 1992; Di Simone et al., 2000). Interestingly, once bound antibodies obtained from 
patients with APS can affect the trophoblast functions in vitro, inducing cell injury and apop-
tosis, inhibition of proliferation and syncitia formation, decreased production of human 
chorionic gonadotrophin, defective secretion of growth factors and impaired invasiveness 
(Figure 2) (Di Simone et al., 2000). ┚2GPI-dependent aPL seem, therefore, to represent the main 
pathogenic autoantibodies in obstetrical APS. Accordingly, it has been hypothesized that most 
of these potentially pathogenic autoantibodies should be absorbed at the placental level, where 
┚2GPI is expressed, and should not be transferred to the fetus.  
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Fig. 2. aPL-mediated inhibition of trophoblast invasiveness and endometrial angiogenesis.  
Placental development has been proposed to be impaired by aPL direct binding to 
trophoblast cells, reducing its invasiveness and inhibiting cell proliferation, syncitia 
formation, secretion of human chorionic gonadotrophin and growth factors. Furthermore, 
aPL have also been suggested to inhibit maternal decidual angiogenesis, providing an 
additional mechanism able to explain placental failure associated to APS. 
Recent findings have underlined a further mechanism by which aPL binding to human 
trophoblast could affect its functions: the aPL-mediated reduction of placental Heparin-
Binding Epidermal Growth Factor–like growth factor (HB-EGF) expression. HB-EGF is a 
member of the EGF family (Raab & Klagsbrun, 1997; Iwamoto & Mekada, 2000). It has been 
shown to induce an invasive trophoblast phenotype in human and mouse blastocysts 
(Martin et al., 1998; Wang J., 2000) and to initiate molecular and cellular changes 
characteristic of decidualization in mice (Paria et al., 2001). HB-EGF is expressed in the 
human placenta during the first trimester, primarily within the villous trophoblast, but also 
in the extravillous cytotrophoblast, predominantly at the sites of cytotrophoblast 
extravillous invasion (Leach et al., 1999). Women with preeclampsia and infants small for 
gestational age display decreased placental expression of HB-EGF (Leach et al., 2002), 
strongly suggesting an association between HB-EGF down-regulation, poor trophoblast 
invasion, and failed physiologic transformation of the spiral arteries occurring in these 
disorders. 
Interestingly, also in placental tissue obtained from women with APS, reduced expression of 
HB-EGF has been found (Di Simone et al., 2010a). Furthermore, polyclonal and monoclonal 
aPL have been shown to bind trophoblast monolayers in vitro significantly reducing the 
synthesis and the secretion of HB-EGF (Di Simone et al., 2010a). The ability of exogenous 
recombinant HB-EGF to reduce the aPL mediated effects on trophoblast cells supports the 
hypothesis of a key pathogenic role of this molecule in mediating APS-related adverse 
pregnancy outcomes. The experimental conditions did not involve complement activation, 
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indicating that aPL may also affect placental tissue through direct, complement-
independent effects, as previously suggested (Pierangeli et al., 2008). 
4.3.2 Endometrial angiogenesis inhibition 
On the maternal side, endometrial endothelial angiogenesis inhibition has been suggested 
to be an additional aPL-mediated mechanism of placental damage (Figure 2). aPL seem to 
selectively bind in vitro to endothelial cells isolated from human endometrium (HEEC) 
and to inhibit endothelial cell differentiation into capillary-like tubular structures, by 
reducing MMP-2 activity and VEGF secretion, via a suppression of NFKB DNA binding 
activity. Such an aPL-mediated inhibition of angiogenesis has also been confirmed in vivo 
in murine models showing a reduced angiogenesis in subcutaneous implanted 
angioreactors in aPL-inoculated mice (Di Simone et al., 2010b). Since it is well known that 
endometrial angiogenesis and decidualization, as well as trophoblast invasion, are 
fundamental prerequisites for successful implantation and the beginning of pregnancy, 
aPL-inhibition of such a central process in human placental development provides an 
important additional mechanism able to explain the association between APS and 
pregnancy complications associated to placental failure, like miscarriage, foetal growth 
restriction and preeclampsia.  
4.4 Inflammation  
It is widely accepted that a physiological pregnancy development requires a fine regulation 
of the maternal immune response during embryo implantation. Acute inflammatory events 
are recognized causes of a negative pregnancy outcome, and proinflammatory mediators, 
such as complement, tumor necrosis factor (TNF), and CC chemokines, have been shown to 
play a role in animal models of aPL-induced foetal loss (Chaouat, 2007).  Intraperitoneal 
injections of large amounts of human IgG with aPL activity to pregnant naive mice after 
embryo implantation induce considerable placental inflammatory damage that results in 
foetal loss and growth retardation. An inflammation-mediated aPL damage has also been 
demonstrated by immunohistochemical and histological examination of murine deciduas, 
showing deposition of human IgG and mouse complement, neutrophil infiltration and local 
TNF secretion, in association with a transient but significant increase in blood TNF levels 
(Holers et al., 2002; Girardi et al., 2003; Berman et al., 2005). Furthermore, it has been 
demonstrated that in response to aPL-generated C5a, neutrophils express TF potentiating 
inflammation in the deciduas and leading to miscarriages in mice (Figure 3). Importantly, 
TF in myeloid cells, but not trophoblasts, seem to be associated with foetal injury, 
suggesting that the site for pathologic TF expression is neutrophils (Redecha et al., 2007). 
The pathogenic mechanism of complement-mediated foetal loss induced by aPL is also 
supported by the protection that deficiency in complement components confers on the 
animals, or that follows from in vivo inhibition of complement (Thurman et al., 2005; Girardi 
et al., 2006). 
In another experimental model of foetal loss, mice deficient in chemokine-binding protein 
D6, a placental receptor that recognizes the majority of inflammatory CC chemokines and 
targets them for degradation, were more susceptible to foetal loss when passively infused 
with a small amount of human aPL IgG than wild-type mice or mice infused with normal 
IgG (Martinez de la Torre et al., 2007). Altogether, these findings suggest that a local acute 
inflammatory response might have a role in experimental aPL-mediated foetal loss. 
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Although C4d and C3b fragments have been shown to be deposited in the placentas of 
patients with APS, analysis of abortive material or full-term placentae from women with 
APS has not provided conclusive information about the pathogenic contributions of acute 
local inflammatory events and complement deposition (Park, 2006; Shamonki et al., 2007). In 
order to confirm this hypothesis more studies on human placentas are required.  
 
 
 
Fig. 3. aPL-mediated activation of complement system and foetal loss. 
Endothelial cells, activated by aPL, express adhesion molecules and activated platelets 
increase expression of glycoprotein IIb-IIIa and synthesis of thromboxane A2, determining a 
procoagulant state (first hit). The occurrence of a second hit, like inflammation, can lead to 
clot formation.  
5. Pregnancy management  
Women with APS should be carefully managed by the physician during pregnancy. A 
clinical manifestations of APS associated to a high risk for maternal health in pregnancy is 
severe pulmonary hypertension, representing a contraindication to pregnancy. Furthermore, 
women with APS should be suggested to delay pregnancy when uncontrolled increase of 
blood pressure or recent thrombotic events have occurred (Ruiz-Irastorza et al., 2008, 2010). 
More than 70% of pregnant women with APS properly managed will have a good 
pregnancy outcome (Bramhan et al., 2010). However, a complete profile of aPL should be 
performed before planning of pregnancy. These tests do not need to be repeated during 
pregnancy, since subsequent negative results after diagnosis do not eliminate the risk of 
complications (Ruiz-Irastorzaet al., 2008, 2010). Frequent prenatal visits and obstetric 
ultrasound, every 2-4 weeks, should be done in order to early detect pregnancy 
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complications like maternal hypertension, proteinuria and other features of preeclampsia, 
placental insufficiency, foetal loss, foetal growth restriction and the need for iatrogenic 
preterm birth (Branch & Khamashta, 2003). Surveillance testing should begin at 32 weeks’ 
gestation, or earlier if placental insufficiency is suspected, and should continue at least every 
week until delivery. Uterine and umbilical artery Doppler assessments are used for the high 
risk for preeclampsia, placental insufficiency, and foetal growth restriction after the 24th 
week of gestation in this category of patients and normal examinations have high negative 
predictive values (Le Thi Huong et al., 2006).  
Nowadays, despite the controversies raised by clinical trials (Kutteh, 1996; Rai et al., 1997; 
Farquharson et al., 2002; Laskin et al., 2009; Noble et al., 2005; Stephenson et al., 2004), the 
gold standard treatment of patients with APS and history of recurrent early miscarriage is a 
combination of either low-dose heparin or low-molecular weight heparin and low-dose 
aspirin (Empson et al., 2005, Bates et al., 2008). Best pregnancy outcomes are achieved with 
heparin started in the early first trimester when a live embryo is detectable by ultrasound. 
For pregnant women with APS who have had a previous thrombotic event, low-dose aspirin 
and therapeutic dose heparin or low-molecular weight heparin anticoagulation are 
recommended (Bates et al., 2008).  
Results from randomised trials do not define optimum treatment for women with foetal 
death (>10 weeks’gestation) or previous early delivery (<34 weeks’gestation) due to severe 
preeclampsia or placental insufficiency. Most experts recommend low-dose aspirin and 
either prophylactic or intermediate-dose heparin (Branch & Khamashta, 2003; Empson et al., 
2005; Bates et al., 2008).  
Use of glucocorticoids to treat pregnant women with APS have been shown to be less 
effective than heparin plus aspirin (Silver et al., 1993; Cowchock et al., 1992) as well as 
administration of intravenous immunoglobulins, either when added to heparin or used 
alone, do not ameliorate pregnancy outcome. However, intravenous immunoglobulins 
treatment should be considered whether classic treatment with aspirin plus heparin is not 
effective (Triolo et al., 2003; Branch et al., 2000; Vaquero et al., 2001), although it has been 
associated to an increased risk of pregnancy loss or premature birth, compared with heparin 
and low-dose aspirin (Empson et al., 2005).  
Vitamin K antagonists (warfarin) are the gold standard treatment of APS clinically 
manifested with thromboses but, because of teratogenic risk, should be avoided between 6 
and 12 weeks’ of gestation. To avoid risk of foetal bleeding, warfarin after 12 weeks’ 
gestation should be given only in exceptional circumstances (Bates et al., 2008; Østensen et 
al., 2004). Furthermore, women with APS should be treated with antithrombotic drug also 
during the post-partum period (Bates et al., 2008). Women with history of thrombosis need 
long-term anticoagulation, and it would be better to switch the treatment to warfarin, as 
soon as possible after delivery. In patients with no previous thrombosis, prophylactic dose 
heparin or low-molecular-weight heparin therapy for 6 weeks after delivery are 
recommended (Bates et al., 2008). Finally, both heparin and warfarin are safe for 
breastfeeding mothers (Østensen et al., 2004). 
6. Conclusions 
Although modern management and treatment of APS in pregnancy significantly ameliorate 
pregnancy outcome, more efforts are needed in order to unravel aPL-mediated pathogenic 
mechanisms still not understood and to open new perspective of therapies of this complex 
and multifactorial syndrome.  
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